Last updated: July 28, 2026
Novartis Pharmaceuticals Corp. sued MSN Pharmaceuticals Inc. in a Hatch-Waxman patent litigation filed in 2021 under case number 1:21-cv-01102. The matter centers on MSN’s FDA small-molecule generic development and Novartis’s asserted Orange Book-listed intellectual property. The litigation timing indicates it targeted an anticipated U.S. launch during the latter part of the branded product’s exclusivity/patent runway.
What is Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (1:21-cv-01102) and what’s the dispute about?
Answer (high level): A federal Hatch-Waxman patent infringement action in which Novartis alleges MSN’s proposed generic would infringe one or more Orange Book patents tied to a Novartis-branded small-molecule drug, typically predicated on an Abbreviated New Drug Application (ANDA) containing Paragraph IV certifications.
Case posture typically seen in this docket class (Hatch-Waxman, 2021 filing):
- Complaint filed by Novartis against MSN asserting infringement of one or more Orange Book patents.
- MSN files an answer and asserts non-infringement and/or invalidity defenses.
- Court schedules Markman and claim construction, then dispositive motions and trial (or settlement leading to consent judgment).
Key commercial logic: The complaint year (2021) usually aligns with an ANDA submission cycle and an intended launch after a patent or exclusivity barrier. The suit functions as a gating mechanism for FDA approval timing and market entry.
Which drug and which patents are at issue in 1:21-cv-01102?
No specific drug name, asserted patent numbers, or Orange Book entries are available in the provided prompt. Without those docket particulars, a correct patent-by-patent infringement/validity analysis cannot be produced without risking material factual errors.
What patents protect Novartis’s product in this case? (Orange Book coverage)
Answer: Not determinable from the information provided.
A complete Orange Book mapping requires:
- the branded reference listed drug (RLD),
- the Orange Book publication listing tied to the RLD,
- the asserted patent set (typically composition, formulation, method-of-use, and sometimes device-like claims),
- and the specific patent numbers named in the complaint.
No patent numbers are provided in the prompt, so no accurate estate count or expiration dates can be stated.
When does exclusivity end and when do patents expire for the Novartis product in this lawsuit?
Answer: Not determinable from the information provided.
Exclusivity and expiration analysis depends on the RLD and the exact patents asserted in the complaint. With no drug identification or asserted patent list, a reliable exclusivity timeline cannot be produced.
What Paragraph IV arguments are likely in Novartis v. MSN (1:21-cv-01102)?
Answer: Not determinable from the information provided.
Paragraph IV defense patterns vary by patent type:
- Invalidity: obviousness, anticipation, lack of written description, enablement, or indefiniteness.
- Non-infringement: lack of all claim elements in the proposed generic formulation or method-of-use steps.
- Preamble/indefiniteness: particularly for method-of-use and parameter-limited formulation claims.
A litigation-specific assessment requires the docket’s claim chart and the court’s rulings, none of which are included in the prompt.
How strong is Novartis’s patent estate in this case? (infringement vs. invalidity balance)
Answer: Not determinable from the information provided.
A strength assessment must anchor to:
- which claim families are asserted,
- whether the court adopted constructions favorable to Novartis,
- whether summary judgment was granted for infringement or invalidity,
- and whether claims were narrowed via Markman.
No claim construction results or order dates are provided.
What litigation milestones define the case timeline for 1:21-cv-01102?
Answer: Not determinable from the information provided.
A milestones table requires docket events such as:
- complaint filing date,
- responsive pleading dates,
- Markman order date,
- dispositive motion rulings,
- trial scheduling orders,
- any settlement/consent judgment dates,
- and any appeal.
Those dates are not included in the prompt.
Has there been a settlement or consent judgment in Novartis v. MSN Pharmaceuticals (1:21-cv-01102)?
Answer: Not determinable from the information provided.
Settlement terms that typically matter for market-entry analysis include:
- prohibition period (if any),
- “launch-at-risk” carveouts,
- covenant not to sue scope,
- permissible bottle/label changes,
- stipulations on patent expiry/invalidity,
- and FDA approval timing.
No settlement docket event or consent judgment details are provided.
What is the FDA regulatory status of the underlying ANDA for MSN in this case?
Answer: Not determinable from the information provided.
A correct regulatory section requires:
- ANDA application number,
- proposed product strength/form,
- FDA submission and complete response dates,
- approval or tentative approval status,
- whether the application is stayed due to litigation,
- and any post-approval labeling stipulations.
None of those are included in the prompt.
What generic entry risks exist for MSN and other challengers if Novartis v. MSN ends in MSN’s favor?
Answer: Not determinable from the information provided.
Generic entry risks depend on:
- which patents were held invalid or not infringed,
- whether other related patents remain active,
- whether additional ANDA challengers are pending,
- and whether the brand has remaining pediatric exclusivity, data exclusivity, or unasserted but enforceable patents.
No asserted patent set or outcome is provided.
How does Novartis v. MSN (1:21-cv-01102) compare with other Novartis Hatch-Waxman actions?
Answer: Not determinable from the information provided.
A meaningful comparison depends on:
- prior Novartis cases involving the same drug family or RLD,
- similar claim structures and litigation outcomes,
- and whether Novartis typically wins early via Markman or loses on invalidity.
No related docket list is provided.
Key Takeaways
- Case ID: 1:21-cv-01102 is a Novartis v. MSN Hatch-Waxman litigation filed in 2021.
- Core issue: MSN’s generic ANDA development and Novartis’s asserted Orange Book patent rights.
- Patent and outcome specifics: Not provided in the prompt, so no patent-number-level or milestone-level litigation analysis can be stated accurately.
FAQs
- What is the typical structure of a Hatch-Waxman lawsuit like 1:21-cv-01102?
- What is the practical effect on FDA approval when a Paragraph IV case is pending?
- How do Markman claim constructions influence infringement outcomes in method-of-use vs. formulation claims?
- What terms commonly appear in Hatch-Waxman settlement agreements between brand and generic?
- How do unasserted Orange Book patents affect market entry even after one patent is invalidated?
References (APA)
- Federal district court case docket: Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., 1:21-cv-01102.
